Foundation Medicine and Its Collaborators to Present New Data at ASCO 2017 Supporting the Integration of Comprehensive Genomic Profiling (CGP) in Personalized Clinical Care in Oncology
--New data, including content from two oral presentations continues to validate the clinical value of molecular information from CGP in guiding treatment towards targeted therapy, immunotherapy, and clinical trials--
"Together these studies highlight the importance of our CGP approach in advancing precision medicine in cancer care and build upon the growing body of evidence supporting its use in clinical practice," said
New results include an oral presentation titled "Comprehensive genomic profiling with loss of heterozygosity to identify therapeutically relevant subsets of ovarian cancer," which shows that CGP can reveal molecular, rather than histologic, patient subsets who may benefit from poly (ADP-ribose) polymerase (PARP) inhibitor targeted therapy or immunotherapy. These results also provide support for insurance coverage and further integration of CGP into clinical trials in ovarian cancer.
Further supporting the integration of CGP at diagnosis, results from health economic and outcomes studies will be presented, demonstrating that early integration of CGP into a patient's clinical and diagnostic work-up leads to improved patient outcomes associated with reasonable incremental costs to the payer that are largely driven by increased survival time on treatment. One poster titled "Estimated Cost of Anti-Cancer Therapy Directed by CGP in a Single-Center Study" discusses estimated anti-cancer drug costs and the associated cost impact of overall survival (OS) for matched vs. unmatched therapy in patients enrolled in a previously reported clinical trial using FoundationOne to guide therapeutic decisions.
In addition, important new studies will be presented on the ability of FoundationACT liquid biopsy assay to identify ESR1 and PIK3CA mutations in metastatic breast cancer, acquired resistance mutations in non-small cell lung cancer and BRCA1/2 reversion mutations in prostate cancer, all of which could help guide treatment decisions for these indications.
Other studies demonstrate the ability of CGP to accelerate clinical trial enrollment. Results from "Accelerating clinical trial enrollment with comprehensive genomic profiling (CGP) and ‘Just-in-Time' clinical trial sites: An index case of a paradigm shift", reveal a new approach for matching patients to clinical trials that focus on rare genomic findings. Combined with a computational matching infrastructure, this approach could accelerate drug development and improve access to novel targeted therapies.
Following is a list of selected abstracts, including those referenced above.
Visit http://info.foundationmedicine.com/annual-meeting-2017 for a complete list of abstracts and to stay connected with
Immunotherapy/TMB Data
- Oral Presentation: Abstract 5512 - Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC),
June 5 , E450ab,8:48am -9:00am - Abstract 9536 - Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes,
June 3 , Hall A,1:15pm -4:45pm - Abstract 4086 - Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC),
June 3 , Hall A,8:00am -11:30am - Abstract 3039 - Mutational burden of tumors with primary site unknown,
June 5 , Hall A,8:00 am -11:30am - Abstract 9072 - BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies,
June 3 , Hall A,8:00am -11:30am
Targeted Therapy Data
- Oral Presentation: Abstract 11001 - Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma,
June 2 , S100bc,3:12pm -3:24pm - Abstract 3583 - Targeted therapy for HER2 driven colorectal cancer,
June 3 , Hall A,8:00am -11:30am
Health Economic Data
- Abstract 6599 - Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in US health plan population,
June 5 , Hall A,1:15pm -4:45pm - Abstract 6605 - Estimated cost of anti-cancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study,
June 5 , Hall A,1:15pm -4:45pm
Liquid Biopsy Data
- Abstract 1016 - Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC),
June 4 , Hall B1,4:45pm -6:00pm - Abstract 9025 - Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC),
June 3 , Hall A,8:00am - 11:30am - Abstract 5024 - BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples,
June 5 , Hall A,1:15pm - 4:45pm - Abstract 4128 - Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with pancreatic ductal adenocarcinoma (PDA),
June 3 , Hall A,8:00am -11:30am
Clinical Trial and Partnerships Data
- Abstract 6539 - Accelerating clinical trial enrollment with comprehensive genomic profiling (CGP) and just-in-time clinical trial sites: An index case of a paradigm shift,
June 5 , Hall A,1:15pm -4:45pm - Abstract 2512 - Personalized, molecularly matched combination therapies for treatment-naïve, lethal malignancies: The I-PREDICT study,
June 5 ,Arie Crown Theater ,11:30am -12:45pm
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the value of comprehensive genomic profiling, including FoundationOne, FoundationOne Heme, FoundationACT and FoundationFocus, and molecular information from CGP, in cancer care, acceleration of clinical trial enrollment, and the development of targeted therapies; the ability of TMB to predict responses to certain types of
View source version on businesswire.com: http://www.businesswire.com/news/home/20170518005422/en/
Media:
pr@foundationmedicine.com
or
Investors:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media